Dorien Peters
Hoogleraar Humane Genetica, in het bijzonder de moleculaire en functionele genetica van nierziekten
- Naam
- Prof.dr. D.J.M. Peters
- Telefoon
- +31 71 526 9490
- d.j.m.peters@lumc.nl
- ORCID iD
- 0000-0001-6974-7143
Dorien J.M. Peters is hoogleraar Humane Genetica, in het bijzonder de moleculaire en functionele genetica van cystenieren, bij de afdeling Humane Genetica in het Leids Universitair Medisch Centrum. Ze ontving in 2013 de Lillian Jean Kaplan International Prize for Advancement in the Understanding of Polycystic Kidney Disease.
Meer informatie over Dorien Peters
Dorien J.M. Peters is hoogleraar Humane Genetica, in het bijzonder de moleculaire en functionele genetica van cystenieren, bij de afdeling Humane Genetica in het Leids Universitair Medisch Centrum.
Ze ontving in 2013 de Lillian Jean Kaplan International Prize for Advancement in the Understanding of Polycystic Kidney Disease.
Moleculaire en functionele genetica
Moleculaire en functionele genetica bestudeert de structuur en functie van genen op moleculair niveau, en hoe moleculaire variaties biologische mechanismen beïnvloeden. We passen een multidisciplinair, state-of-the-art programma toe om inzicht te krijgen in de genetische, pathofysiologische en functionele mechanismen van erfelijke aandoeningen, met name polycysteuse nierziekte (cystenieren). Het uiteindelijke doel van ons onderzoek is het ontwikkelen van nieuwe therapeutische behandelingen. Verschillende modelsystemen worden gebruikt om een diepgaande analyse van de moleculaire veranderingen uit te voeren, nieuwe aangrijpingspunten voor medicijnen te identificeren en potentiële therapieën te testen. Dorien Peters heeft door de jaren heen verschillende ‘multicenter’ onderzoeksconsortia opgezet en gecoördineerd voor onderzoek aan cystenieren (TranCYST, DIPAK, DRUGtrain), om de vertaling van fundamenteel en preklinisch onderzoek naar de kliniek te vergemakkelijken. Ons onderzoek sluit aan bij de Nationale wetenschapsagenda (punt 90, 94 en 102) en de strategisch agenda ‘Nierziekte de Baas’ van de Nierstichting.
Wetenschappelijke carrière
Dorien J.M. Peters deed haar promotieonderzoek aan de Universiteit Leiden, bij de afdeling Celbiologie en Genetica van de faculteit der Wiskunde en Natuurwetenschappen.
Zij behaalde haar doctoraat op 13 februari 1991 en de titel van haar proefschrift luidt ‘Regulation of cAMP-induced gene expression in Dictyostelium discoideum’. Vervolgens werd ze postdoc bij de afdeling Humane Genetica van het LUMC. In 1999 werd ze groepsleider, eerst als universitair docent, in 2000 als universitair hoofddocent en sinds 2014 als hoogleraar. Zij sprak haar inaugurele rede, getiteld "Het belang van de context" uit op 17 april 2015.
Ze is ook voorzitter van de opleidingscommissie Biomedisch wetenschappen (BSc en MSc).
Betrokken onderzoeksthema's LUMC:
Prijzen en eervolle benoemingen
Dorien J.M. Peters ontving in 2013 de ‘Lillian Jean Kaplan International Prize for Advancement in the Understanding of Polycystic Kidney Disease’ voor excellent onderzoek en leiderschap in onderzoek naar cystenieren. Ze ontving in 1996 de Nefrologieprijs van de Nederlandse Vereniging voor Nefrologie.
Hoogleraar Humane Genetica, in het bijzonder de moleculaire en functionele genetica van nierziekten
- Faculteit Geneeskunde
- Divisie 4
- Humane Genetica
- Song, X.W.; Leonhard, W.N.; Kanhai, A.A.; Steinberg, G.R.; Pei, Y.R. & Peters, D.J.M. (2023), Preclinical evaluation of tolvaptan and salsalate combination therapy in a Pkd1-mouse model, Frontiers in Molecular Biosciences 10.
- Megen, W.H. van; Canki, E.; Wagenaar, V.H.A.; Waes, C.R.M.M. van; Peters, D.J.M.; Asbeck-Van der Wijst, J. van & Hoenderop, J.G.J. (2023), Fluid shear stress stimulates ATP release without regulating purinergic gene expression in the renal inner medullary collecting duct, The FASEB Journal 37(11).
- Carotti, V.; Megen, W.H. van; Rigalli, J.P.; Barros, E.R.; Sommers, V.; Rutten, L.; Sommerdijk, N.; Peters, D.J.M.; Wijst, J.V.V. van van der & Hoenderop, J.G.J. (2023), Extracellular vesicles contribute to early cyst development in autosomal dominant polycystic kidney disease by cell-to-cell communication, The FASEB Journal 37(7).
- Cristea, I.; Abarca, H.; Mellgren, A.E.C.; Trubnykova, M.; Mehrasa, R.; Peters, D.J.M.; Houge, G.; Hennekam, R.C.M.; Rodahl, E.; Bruland, O. & Bredrup, C. (2023), A Pellino-2 variant is associated with constitutive NLRP3 inflammasome activation in a family with ocular pterygium-digital keloid dysplasia, FEBS Letters 597(9): 1290-1299.
- Kanhai, A.A.; Sánchez-López, E.; Kuipers, T.B.; Klinken, J.B. van; Dijkstra, K.L.; Veen, I. van der; Baelde, H.J.; Song, X.W.; Pei, Y.; Mei, H.L.; Leonhard, W.N.; Mayboroda, O.A. & Peters, D.J.M. (2023), Short salsalate administration affects cell proliferation, metabolism, and inflammation in polycystic kidney disease, iScience 26(11).
- Knol, M.G.E.; Bais, T.; Geertsema, P.; Connelly, M.A.; Bakker, S.J.L.; Gansevoort, R.T.; Gastel, M.D.A. van & DIPAK Consortium (2023), Higher beta-hydroxybutyrate ketone levels associated with a slower kidney function decline in ADPKD, Nephrology Dialysis Transplantation 39(5).
- Novella-Rausell, C.; Grudniewska, M.; Peters, D.J.M. & Mahfouz, A. (2023), A comprehensive mouse kidney atlas enables rare cell population characterization and robust marker discovery, iScience 26(6).
- Hamzaoui, M.; Groussard, D.; Nezam, D.; Djerada, Z.; Lamy, G.; Tardif, V.; Dumesnil, A.; Renet, S.; Brunel, V.; Peters, D.J.M.; Chevalier, L.; Hanoy, M.; Mulder, P.; Richard, V.; Bellien, J. & Guerrot, D. (2022), Endothelium-specific deficiency of polycystin-1 promotes hypertension and cardiovascular disorders, Hypertension 79(11): 2542-2551.
- Cordeiro, L.M.D.; Bainbridge, L.; Devisetty, N.; McDougal, D.H.; Peters, D.J.M. & Chhabra, K.H. (2022), Loss of function of renal Glut2 reverses hyperglycaemia and normalises body weight in mouse models of diabetes and obesity, Diabetologia 65(6): 1032-1047.
- Dekker, S.E.I.; Verhoeven, A.; Frey, D.; Soonawala, D.; Peters, D.J.M.; Mayboroda, O.A. & Fijter, J.W. de (2022), Change in urinary myoinositol/citrate ratio associates with progressive loss of renal function in ADPKD patients, American Journal of Nephrology 53(6): 470-480.
- Kramers, B.J.; Koorevaar, I.W.; Gastel, M.D.A. van; Goor, H. van; Hallows, K.R.; Heerspink, H.L.; Li, H.; Leonhard, W.N.; Peters, D.J.M.; Qiu, J.D.; Touw, D.J.; Gansevoort, R.T. & Meijer, E. (2022), Effects of hydrochlorothiazide and metformin on aquaresis and nephroprotection by a vasopressin V2 receptor antagonist in ADPKD A randomized crossover trial, Clinical Journal of the American Society of Nephrology 17(4).
- Rocchetti, M.T.; Pesce, F.; Matino, S.; Piscopo, G.; Bari, I. di; Trepiccione, F.; Capolongo, G.; Perniola, M.A.; Song, X.W.; Khowaja, S.; Haghighi, A.; Peters, D.; Paolicelli, S.; Pontrelli, P.; Netti, G.S.; Ranieri, E.; Capasso, G.; Moschetta, M.; Pei, Y.; Gesualdo, L. & Studio PRE MED MED PREcisione Prog (2022), Urinary epidermal growth factor/monocyte chemotactic peptide 1 ratio as non-invasive predictor of Mayo clinic imaging classes in autosomal dominant polycystic kidney disease, Journal of Nephrology 36.
- Senum, S.R.; Li, Y.M.; Benson, K.A.; Joli, G.; Olinger, E.; Lavu, S.; Madsen, C.D.; Gregory, A.V.; Neatu, R.; Kline, T.L.; Audrezet, M.P.; Outeda, P.; Nau, C.B.; Meijer, E.; Ali, H.; Steinman, T.I.; Mrug, M.; Phelan, P.J.; Watnick, T.J.; Peters, D.J.M.; Ong, A.C.M.; Conlon, P.J.; Perrone, R.D.; Gall, E.C.L.; Hogan, M.C.; Torres, V.E.; Saver, J.A.; Harris, P.C.; Genomics England Res Consortium; HALT PKD; CRISP; DIPAK; ADPKD Modifier & TAME PKD studies (2022), Monoallelic IFT140 pathogenic variants are an important cause of the autosomal dominant polycystic kidney-spectrum phenotype, American Journal of Human Genetics 109(1): 136-156.
- Heida, J.E.; Gansevoort, R.T.; Messchendorp, A.L.; Meijer, E.; Casteleijn, N.F.; Boertien, W.E.; Zittema, D. & DIPAK Consortium (2021), Use of the urine-to-plasma urea ratio to predict ADPKD progression, Clinical Journal of the American Society of Nephrology 16(2): 204-212.
- Aapkes, S.E.; Haas, R.J. de; Bernts, L.H.P.; Blijdorp, C.J.; Dekker, S.E.I.; Gastel, M.D.A. van; Meijer, E.; Veldman, A.; Drenth, J.P.H.; Gansevoort, R.T. & DIPAK Consortium (2021), Incident gallstones during somatostatin analog treatment are associated with acute biliary complications especially after discontinuation, Drugs in R&D 21(2): 179-188.
- Blijdorp, C.J.; Severs, D.; Musterd-Bhaggoe, U.M.; Gansevoort, R.T.; Zietse, R.; Hoorn, E.J. & DIPAK Consortium (2021), Serum bicarbonate is associated with kidney outcomes in autosomal dominant polycystic kidney disease, Nephrology Dialysis Transplantation 36(12): 2248-2255.
- Kanhai, A.A.; Bange, H.; Verburg, L.; Dijkstra, K.L.; Price, L.S.; Peters, D.J.M. & Leonhard, W.N. (2020), Renal cyst growth is attenuated by a combination treatment of tolvaptan and pioglitazone, while pioglitazone treatment alone is not effective, Scientific Reports 10(1).
- Dekker, S.E.I.; Verhoeven, A.; Soonawala, D.; Peters, D.J.M.; Fijter, J.W. de; Mayboroda, O.A. & DIPAK Consortium (2020), Urinary metabolites associate with the rate of kidney function decline in patients with autosomal dominant polycystic kidney disease, PLoS ONE 15(5).
- Lannoy, M.; Valluru, M.K.; Chang, L.J.; Abdela-Ali, F.; Peters, D.J.M.; Streets, A.J. & Ong, A.C.M. (2020), The positive effect of selective prostaglandin E2 receptor EP2 and EP4 blockade on cystogenesis in vitro is counteracted by increased kidney inflammation in vivo, Kidney International 98(2): 404-419.
- Messchendorp, A.L.; Casteleijn, N.F.; Meijer, E.; Gansevoort, R.T.; Drenth, J.P.; Fijter, J.W. de; Peters, D.J.M.; Visser, F.W.; Wetzels, J.F.; Zietse, R. & DIPAK Consortium Investigators (2020), Somatostatin in renal physiology and autosomal dominant polycystic kidney disease, Nephrology Dialysis Transplantation 35(8): 1306-1316.
- Verschuren, E.H.J.; Castenmiller, C.; Peters, D.J.M.; Arjona, F.J.; Bindels, R.J.M. & Hoenderop, J.G.J. (2020), Sensing of tubular flow and renal electrolyte transport, Nature Reviews Nephrology 16(6): 337-351.
- Kramers, B.J.; Koorevaar, I.W.; Drenth, J.P.H.; Fijter, J.W. de; Neto, A.G.; Peters, D.J.M.; Vart, P.; Wetzels, J.F.; Zietse, R.; Gansevoort, R.T. & Meijer, E. (2020), Salt, but not protein intake, is associated with accelerated disease progression in autosomal dominant polycystic kidney disease, Kidney International 98(4): 989-998.
- Formica, C.; Kunnen, S.; Dauwerse, J.G.; Mullick, A.E.; Dijkstra, K.L.; Scharpfenecker, M. & Peters, D.J.M. (2020), Reducing YAP expression in Pkd1 mutant mice does not improve the cystic phenotype, Journal of Cellular and Molecular Medicine 24(15): 8876-8882.
- Malas, T.B.; Leonhard, W.N.; Bange, H.; Granchi, Z.; Hettne, K.M.; Westen, G.J.P. van; Price, L.S.; Hoen, P.A.C. 't & Peters, D.J.M. (2020), Prioritization of novel ADPKD drug candidates from disease-stage specific gene expression profiles, EBioMedicine 51.
- Losekoot, M.; Meijer, E.; Hagen, E.C.; Belostotsky, V.; Borst, M. de; Tholens, A.; Phylipsen, M.; Pei, Y.; Gansevoort, R.T. & Peters, D.J.M. (2020), Polycystic kidney disease caused by bilineal inheritance of truncating PKD1 as well as PKD2 mutations, Kidney International Reports 5(10): 1828-1832.
- Verschuren, E.H.J.; Rigalli, J.P.; Castenmiller, C.; Rohrbach, M.U.; Bindels, R.J.M.; Peters, D.J.M.; Arjona, F.J. & Hoenderop, J.G.J. (2020), Pannexin-1 mediates fluid shear stress-sensitive purinergic signaling and cyst growth in polycystic kidney disease, FASEB Journal 34(5): 6382-6398.
- Formica, C. & Peters, D.J.M. (2020), Molecular pathways involved in injury-repair and ADPKD progression, Cellular Signalling 72.
- Booij, T.H.; Leonhard, W.N.; Bange, H.; Yan, K.; Fokkelman, M.; Plugge, A.J.; Veraar, K.A.M.; Dauwerse, J.G.; Westen, G.J.P. van; Water, B. van de; Price, L.S. & Peters, D.J.M. (2020), In vitro 3D phenotypic drug screen identifies celastrol as an effective in vivo inhibitor of polycystic kidney disease, Journal of Molecular Cell Biology 12(8): 644-653.
- Kenter, A.T.; Rentmeester, E.; Riet, J. van; Boers, R.; Boers, J.; Ghazvini, M.; Xavier, V.J.; Leenders, G.J.L.H. van; Verhagen, P.C.M.S.; Til, M.E. van; Eussen, B.; Losekoot, M.; Klein, A. de; Peters, D.J.M.; IJcken, W.F.J. van; Werken, H.J.G. van de; Zietse, R.; Hoorn, E.J.; Jansen, G. & Gribnau, J.H. (2020), Cystic renal-epithelial derived induced pluripotent stem cells from polycystic kidney disease patients, Stem Cells Translational Medicine 9(4): 478-490.
- Aerts, R.M.M. van; Kievit, W.; D'Agnolo, H.M.A.; Blijdorp, C.J.; Casteleijn, N.F.; Dekker, S.E.I.; Fijter, J.W. de; Gastel, M. van; Gevers, T.J.; Laarschot, L.F.M. van de; Lantinga, M.A.; Losekoot, M.; Meijer, E.; Messchendorp, A.L.; Neijenhuis, M.K.; Pena, M.J.; Peters, D.J.M.; Salih, M.; Soonawala, D.; Spithoven, E.M.; Visser, F.W.; Wetzels, J.F.; Zietse, R.; Gansevoort, R.T.; Drenth, J.P.H. & DIPAK-1 Investigators (2019), Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease, Gastroenterology 157(2): 481-+.
- Sanchez-Lopez, E.; Kammeijer, G.S.M.; Crego, A.L.; Marina, M.L.; Ramautar, R.; Peters, D.J.M. & Mayboroda, O.A. (2019), Sheathless CE-MS based metabolic profiling of kidney tissue section samples from a mouse model of Polycystic Kidney Disease, Scientific Reports 9.
- Dekker Shosha, Verhoeven Aswin, Soonawala Darius, Peters Dorien J. M., Mayboroda Oleg A. & De Fijter Johan W. (2019), URINARY ALANINE/CITRATE RATIO ASSOCIATES WITH THE RATE OF EGFR DECLINE IN PATIENTS WITH ADPKD, Nephrology Dialysis Transplantation 34: 366-366.
- Malas, T.B.; Vlietstra, W.J.; Kudrin, R.; Starikov, S.; Charrout, M.; Roos, M.; Peters, D.J.M.; Kors, J.A.; Vos, R.; Hoen, P.A.C. 't; Mulligen, E.M. van & Hettne, K.M. (2019), Drug prioritization using the semantic properties of a knowledge graph, Scientific Reports 9.
- Shi, H.L.; Leonhard, W.N.; Sijbrandi, N.J.; Steenbergen, M.J. van; Fens, M.H.A.M.; Dikkenberg, J.B. van de; Torano, J.S.; Peters, D.J.M.; Hennink, W.E. & Kok, R.J. (2019), Folate-dactolisib conjugates for targeting tubular cells in polycystic kidneys, Journal of Controlled Release 293: 113-125.
- Formica, C.; Happe, H.; Veraar, K.A.M.; Vortkamp, A.; Scharpfenecker, M.; McNeill, H. & Peters, D.J.M. (2019), Four-jointed knock-out delays renal failure in an ADPKD model with kidney injury, Journal of Pathology 249(1): 114-125.
- Messchendorp, A.L.; Meijer, E.; Visser, F.W.; Engels, G.E.; Kappert, P.; Losekoot, M.; Peters, D.J.M.; Gansevoort, R.T. & DIPAK-1 Study Investigators (2019), Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors, American Journal of Nephrology 50(5): 375-385.
- Leonhard, W.N.; Song, X.W.; Kanhai, A.A.; Iliuta, I.A.; Bozovic, A.; Steinberg, G.R.; Peters, D.J.M. & Pei, Y. (2019), Salsalate, but not metformin or canagliflozin, slows kidney cyst growth in an adult-onset mouse model of polycystic kidney disease, EBioMedicine 47: 436-445.
- Verschuren, E.H.J.; Hoenderop, J.G.J.; Peters, D.J.M.; Arjona, F.J. & Bindels, R.J.M. (2019), Tubular flow activates magnesium transport in the distal convoluted tubule, FASEB Journal 33(4): 5034-5044.
- Messchendorp, A.L.; Spithoven, E.M.; Casteleijn, N.F.; Dam, W.A.; Born, J. van den; Tonnis, W.F.; Gaillard, C.A.J.M.; Meijer, E.; Drenth, J.; Fijter, J.W. de; Gansevoort, R.T.; Peters, D.J.M.; Wetzels, J.F.M.; Zietse, R. & DIPAK Consortium (2018), Association of plasma somatostatin with disease severity and progression in patients with autosomal dominant polycystic kidney disease, BMC Nephrology 19.
- Messchendorp, A.L.; Meijer, E.; Boertien, W.E.; Engels, G.E.; Casteleijn, N.F.; Spithoven, E.M.; Losekoot, M.; Burgerhof, J.G.M.; Peters, D.J.M.; Gansevoort, R.T. & DIPAK Consortium (2018), Urinary Biomarkers to Identify Autosomal Dominant Polycystic Kidney Disease Patients With a High Likelihood of Disease Progression, Kidney International Reports 3(2): 291-301.
- Lin, C.; Happe, H.; Veraar, K.; Scharpfenecker, M.; Peters, D.J.M. & Dipak Consortium (2018), The expression of somatostatin receptor 2 decreases during cyst growth in mice with polycystic kidney disease, Experimental Biology and Medicine 243(13): 1092-1098.
- Dafinger, C.; Rinschen, M.M.; Borgal, L.; Ehrenberg, C.; Basten, S.G.; Franke, M.; Hone, M.; Rauh, M.; Gobel, H.; Bloch, W.; Wunderlich, F.T.; Peters, D.J.M.; Tasche, D.; Mishra, T.; Habbig, S.; Dotsch, J.; Muller, R.U.; Bruning, J.C.; Persigehl, T.; Giles, R.H.; Benzing, T.; Schermer, B. & Liebau, M.C. (2018), Targeted deletion of the AAA-ATPase Ruvbl1 in mice disrupts ciliary integrity and causes renal disease and hydrocephalus, Experimental and Molecular Medicine 50.
- Verschuren, E.H.J.; Mohammed, S.G.; Leonhard, W.N.; Overmars-Bos, C.; Veraar, K.; Hoenderop, J.G.J.; Bindels, R.J.M.; Peters, D.J.M. & Arjona, F.J. (2018), Polycystin-1 dysfunction impairs electrolyte and water handling in a renal precystic mouse model for ADPKD, AJP - Renal Physiology 315(3): F537-F546.
- Kraus, A.; Peters, D.J.M.; Klanke, B.; Weidemann, A.; Willam, C.; Schley, G.; Kunzelmann, K.; Eckardt, K.U. & Buchholz, B. (2018), HIF-1 alpha promotes cyst progression in a mouse model of autosomal dominant polycystic kidney disease, Kidney International 94(5): 887-899.
- Bergmann, C.; Guay-Woodford, L.M.; Harris, P.C.; Horie, S.; Peters, D.J.M. & Torres, V.E. (2018), Polycystic kidney disease, Nature Reviews Disease Primers 4.
- Harris, T.; Sandford, R.; Coninck, B. de; Devuyst, O.; Drenth, J.P.H.; Ecder, T.; Kent, A.; Gansevoort, R.T.; Gorriz, J.L.; Ong, A.C.M.; Pirson, Y.; Torres, V.E.; Budde, K.; Clement, D.; Derchi, L.E.; Eleftheroudi, M.; Levtchenko, E.; Peters, D.; Poppel, H. van & Vanholder, R. (2018), European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care, Nephrology Dialysis Transplantation 33(4): 563-573.
- Meijer, E.; Visser, F.W.; Aerts, R.M.M. van; Blijdorp, C.J.; Casteleijn, N.F.; D'Agnolo, H.M.A.; Dekker, S.E.I.; Drenth, J.P.H.; Fijter, J. de; Gastel, M.D.A. van; Gevers, T.J.; Lantinga, M.A.; Losekoot, M.; Messchendorp, A.L.; Neijenhuis, M.K.; Pena, M.J.; Peters, D.J.M.; Salih, M.; Soonawala, D.; Spithoven, E.M.; Wetzels, J.F.; Zietse, R.; Gansevoort, R.T. & DIPAK-1 Investigators (2018), Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease The DIPAK 1 Randomized Clinical Trial, Journal of the American Medical Association 320(19): 2010-2019.
- Kunnen, S.J.; Malas, T.B.; Semeins, C.M.; Bakker, A.D. & Peters, D.J.M. (2018), Comprehensive transcriptome analysis of fluid shear stress altered gene expression in renal epithelial cells, Journal of Cellular Physiology 233(4): 3615-3628.
- Kunnen, S.J.; Malas, T.B.; Formica, C.; Leonhard, W.N.; Hoen, P.A.C. 't & Peters, D.J.M. (2018), Comparative transcriptomics of shear stress treated Pkd1(-/-) cells and pre-cystic kidneys reveals pathways involved in early polycystic kidney disease, Biomedicine and Pharmacotherapy 108: 1123-1134.
- Booij T.H., Bange H., Leonhard W.N., Yan K., Fokkelman M., Kunnen S.J., Dauwerse J.G., Qin Y., Water B. van de, Westen G.J.P. van, Peters D.J.M. & Price L.S. (2017), High-Throughput Phenotypic Screening of Kinase Inhibitors to Identify Drug Targets for Polycystic Kidney Disease, Slas Discovery 22(8): 974-984.
- Kunnen, S.J.; Leonhard, W.N.; Semeins, C.; Hawinkels, L.J.A.C.; Poelma, C.; Dijke, P. ten; Bakker, A.; Hierck, B.P. & Peters, D.J.M. (2017), Fluid shear stress-induced TGF-beta/ALK5 signaling in renal epithelial cells is modulated by MEK1/2, Cellular and Molecular Life Sciences 74(12): 2283-2298.
- Streets, A.J.; Magayr, T.A.; Huang, L.H.; Vergoz, L.; Rossetti, S.; Simms, R.J.; Harris, P.C.; Peters, D.J.M. & Ong, A.C.M. (2017), Parallel microarray profiling identifies ErbB4 as a determinant of cyst growth in ADPKD and a prognostic biomarker for disease progression, AJP - Renal Physiology 312(4): F577-F588.
- Lantinga, M.A.; D'Agnolo, H.M.A.; Casteleijn, N.F.; Fijter, J.W. de; Meijer, E.; Messchendorp, A.L.; Peters, D.J.M.; Salih, M.; Spithoven, E.M.; Soonawala, D.; Visser, F.W.; Wetzels, J.F.M.; Zietse, R.; Drenth, J.P.H.; Gansevoort, R.T. & DIPAK Consortium (2017), Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study, Drug Safety 40(2): 153-167.
- D'Agnolo, H.M.A.; Casteleijn, N.F.; Gevers, T.J.G.; Fijter, H. de; Gastel, M.D.A. van; Messchendorp, A.L.; Peters, D.J.M.; Salih, M.; Soonawala, D.; Spithoven, E.M.; Visser, F.W.; Wetzels, J.F.M.; Zietse, R.; Gansevoort, R.T. & Drenth, J.P.H. (2017), The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease, American Journal of Nephrology 46(3): 239-248.
- Booij, T.H.; Bange, H.; Leonhard, W.N.; Yan, K.; Fokkelman, M.; Kunnen, S.J.; Dauwerse, J.G.; Qin, Y.; Water, B. van de; Westen, G.J.P. van; Peters, D.J.M. & Price, L.S. (2017), High-Throughput Phenotypic Screening of Kinase Inhibitors to Identify Drug Targets for Polycystic Kidney Disease, Slas Discovery 22(8): 974-984.
- Bailey, S.T.; Smith, A.M.; Kardos, J.; Wobker, S.E.; Wilson, H.L.; Krishnan, B.; Saito, R.; Lee, H.J.; Zhang, J.; Eaton, S.C.; Williams, L.A.; Manocha, U.; Peters, D.J.; Pan, X.C.; Carroll, T.J.; Felsher, D.W.; Walter, V.; Zhang, Q.; Parker, J.S.; Yeh, J.J.; Moffitt, R.A.; Leung, J.Y. & Kim, W.Y. (2017), MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma, Nature Communications 8.
- Casteleijn, N.F.; Gastel, M.D.A. van; Blankestijn, P.J.; Drenth, J.P.H.; Jager, R.L. de; Leliveld, A.M.; Stellema, R.; Wolff, A.P.; Groen, G.J.; Gansevoort, R.T. & DIPAK Consortium (2017), Novel treatment protocol for ameliorating refractory, chronic pain in patients with autosomal dominant polycystic kidney disease, Kidney International 91(4): 972-981.
- Sanchez-Lopez, E.; Happe, H.; Steenvoorden, E.; Crego, A.L.; Marina, M.L.; Peters, D.J.M.; Mayboroda, O.A. & Dutch DIPAK Consortium (2017), A cross-platform metabolomics workflow for volume-restricted tissue samples: application to an animal model for polycystic kidney disease, Molecular BioSystems 13(10): 1940-1945.
- Fragiadaki, M.; Lannoy, M.; Themanns, M.; Maurer, B.; Leonhard, W.N.; Peters, D.J.M.; Moriggl, R. & Ong, A.C.M. (2017), STAT5 drives,abnormal proliferation in autosomal dominant polycystic kidney disease, Kidney International 91(3): 575-586.
- Malas, T.B.; Formica, C.; Leonhard, W.N.; Rao, P.; Granchi, Z.; Roos, M.; Peters, D.J.M. & Hoen, P.A.C. 't (2017), Meta-analysis of polycystic kidney disease expression profiles defines strong involvement of injury repair processes, AJP - Renal Physiology 312(4): F806-F817.
- Borras, D.M.; Vossen, R.H.A.M.; Liem, M.; Buermans, H.P.J.; Dauwerse, H.; Heusden, D. van; Gansevoort, R.T.; Dunnen, J.T. den; Janssen, B.; Peters, D.J.M.; Losekoot, M. & Anvar, S.Y. (2017), Detecting PKD1 variants in polycystic kidney disease patients by single-molecule long-read sequencing, Human Mutation 38(7): 870-879.
- Dauwerse, J.G.; Belzen, M. van; Haeringen, A. van; Santen, G. van; Lans, C. van de; Rahikkala, E.; Garavelli, L.; Breuning, M.; Hennekam, R. & Peters, D. (2016), Analysis of mutations within the intron20 splice donor site of CREBBP in patients with and without classical RSTS, European Journal of Human Genetics 24(11): 1639-1643.
- Huang, J.L.; Woolf, A.S.; Kolatsi-Joannou, M.; Baluk, P.; Sandford, R.N.; Peters, D.J.M.; McDonald, D.M.; Price, K.L.; Winyard, P.J.D. & Long, D.A. (2016), Vascular Endothelial Growth Factor C for Polycystic Kidney Diseases, Journal of the American Society of Nephrology 27(1): 69-77.
- Kraus, A.; Grampp, S.; Goppelt-Struebe, M.; Schreiber, R.; Kunzelmann, K.; Peters, D.J.M.; Leipziger, J.; Schley, G.; Schodel, J.; Eckardt, K.U. & Buchholz, B. (2016), P2Y2R is a direct target of HIF-1 alpha and mediates secretion-dependent cyst growth of renal cyst-forming epithelial cells, Purinergic Signalling 12(4): 687-695.
- Menke, L.A.; Belzen, M.J. van; Alders, M.; Cristofoli, F.; Ehmke, N.; Fergelot, P.; Foster, A.; Gerkes, E.H.; Hoffer, M.J.V.; Horn, D.; Kant, S.G.; Lacombe, D.; Leon, E.; Maas, S.M.; Melis, D.; Muto, V.; Park, S.M.; Peeters, H.; Peters, D.J.M.; Pfundt, R.; Ravenswaaij-Arts, C.M.A. van; Tartaglia, M.; Hennekam, R.C.M. & DDD Study (2016), CREBBP mutations in individuals without Rubinstein-Taybi syndrome phenotype, American Journal of Medical Genetics Part A 170(10): 2681-2693.
- Bienaime, F.; Muorah, M.; Yammine, L.; Burtin, M.; Nguyen, C.; Baron, W.; Garbay, S.; Viau, A.; Broueilh, M.; Blanc, T.; Peters, D.; Poli, V.; Anglicheau, D.; Friedlander, G.; Pontoglio, M.; Gallazzini, M. & Terzi, F. (2016), Stat3 Controls Tubulointerstitial Communication during CKD, Journal of the American Society of Nephrology 27(12): 3690-3705.
- Zittema, D.; Versteeg, I.B.; Gansevoort, R.T.; Goor, H. van; Heer, E. de; Veraar, K.A.M.; Peters, D.J.M. & Meijer, E. (2016), Dose-Titrated Vasopressin V2 Receptor Antagonist Improves Renoprotection in a Mouse Model for Autosomal Dominant Polycystic Kidney Disease, American Journal of Nephrology 44(3): 194-203.
- Leonhard, W.N.; Happe, H. & Peters, D.J.M. (2016), Variable Cyst Development in Autosomal Dominant Polycystic Kidney Disease: The Biologic Context, Journal of the American Society of Nephrology 27(12): 3530-3538.
- Rutten, J.W.; Dauwerse, H.G.; Peters, D.J.M.; Goldfarb, A.; Venselaar, H.; Haffner, C.; Ommen, G.J.B. van; Aartsma-Rus, A.M. & Oberstein, S.A.J.L. (2016), Therapeutic NOTCH3 cysteine correction in CADASIL using exon skipping: in vitro proof of concept, Brain 139: 1123-1135.
- Salih, M.; Demmers, J.A.; Berstarosti, K.; Leonhard, W.N.; Losekoot, M.; Kooten, C. van; Gansevoort, R.T.; Peters, D.J.M.; Zietse, R.; Hoorn, E.J. & DIPAK Consortium (2016), Proteomics of Urinary Vesicles Links Plakins and Complement to Polycystic Kidney Disease, Journal of the American Society of Nephrology 27(10): 3079-3092.
- Fergelot, P.; Belzen, M. van; Gils, J. van; Afenjar, A.; Armour, C.M.; Arveiler, B.; Beets, L.; Burglen, L.; Busa, T.; Collet, M.; Deforges, J.; Vries, B.B.A. de; Garrido, E.D.; Dorison, N.; Dupont, J.; Francannet, C.; Garcia-Minaur, S.; Vila, E.G.; Gebre-Medhin, S.; Querol, B.G.; Genevieve, D.; Gerard, M.; Gervasini, C.G.; Goldenberg, A.; Josifova, D.; Lachlan, K.; Maas, S.; Maranda, B.; Moilanen, J.S.; Nordgren, A.; Parent, P.; Rankin, J.; Reardon, W.; Rio, M.; Roume, J.; Shaw, A.; Smigiel, R.; Sojo, A.; Solomon, B.; Stembalska, A.; Stumpel, C.; Suarez, F.; Terhal, P.; Thomas, S.; Touraine, R.; Verloes, A.; Vincent-Delorme, C.; Wincent, J.; Peters, D.J.M.; Bartsch, O.; Larizza, L.; Lacombe, D. & Hennekam, R.C. (2016), Phenotype and Genotype in 52 Patients with Rubinstein-Taybi Syndrome Caused by EP300 Mutations, American Journal of Medical Genetics Part A 170(12): 3069-3082.
- Calcagni, A.; Kors, L.; Verschuren, E.; Cegli, R. de; Zampelli, N.; Nusco, E.; Confalonieri, S.; Bertalot, G.; Pece, S.; Settembre, C.; Malouf, G.G.; Leemans, J.C.; Heer, E. de; Salvatore, M.; Peters, D.J.M.; Fiore, P.P. di & Ballabio, A. (2016), Modeling TFE renal cell carcinoma in mice reveals a critical role of WNT signaling, eLife 5.
- Cnossen, W.R.; Morsche, R.H.M.T.; Hoischen, A.; Gilissen, C.; Venselaar, H.; Mehdi, S.; Bergmann, C.; Losekoot, M.; Breuning, M.H.; Peters, D.J.M.; Veltman, J.A. & Drenth, J.P.H. (2016), LRP5 variants may contribute to ADPKD, European Journal of Human Genetics 24(2): 237-242.
- Leonhard, W.N.; Kunnen, S.J.; Plugge, A.J.; Pasternack, A.; Jianu, S.B.T.; Veraar, K.; Bouazzaoui, F. el; Hoogaars, W.M.H.; Dijke, P. ten; Breuning, M.H.; Heer, E. de; Ritvos, O. & Peters, D.J.M. (2016), Inhibition of Activin Signaling Slows Progression of Polycystic Kidney Disease, Journal of the American Society of Nephrology 27(12): 3589-3599.
- Kraus, A.; Schley, G.; Kunzelmann, K.; Schreiber, R.; Peters, D.J.M.; Stadler, R.; Eckardt, K.U. & Buchholz, B. (2016), Glucose promotes secretion-dependent renal cyst growth, Journal of Molecular Medicine 94(1): 107-117.
- Antignac, C.; Calvet, J.P.; Germino, G.G.; Grantham, J.J.; Guay-Woodford, L.M.; Harris, P.C.; Hildebrandt, F.; Peters, D.J.M.; Somlo, S.; Torres, V.E.; Walz, G.; Zhou, J. & Yu, A.S.L. (2015), The Future of Polycystic Kidney Disease Research-As Seen By the 12 Kaplan Awardees, Journal of the American Society of Nephrology 26(9): 2081-2095.
- Zhou, X.; Fan, L.X.; Peters, D.J.M.; Trudel, M.; Bradner, J.E. & Li, X.G. (2015), Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD, Human Molecular Genetics 24(14): 3982-3993.
- Leonhard, W.N.; Zandbergen, M.; Veraar, K.; Berg, S. van den; Weerd, L. van der; Breuning, M.; Heer, E. de & Peters, D.J.M. (2015), Scattered Deletion of PKD1 in Kidneys Causes a Cystic Snowball Effect and Recapitulates Polycystic Kidney Disease, Journal of the American Society of Nephrology 26(6): 1322-1333.
- Chen, L.; Zhou, X.; Fan, L.X.; Yao, Y.; Swenson-Fields, K.I.; Gadjeva, M.; Wallace, D.P.; Peters, D.J.M.; Yu, A.; Grantham, J.J. & Li, X.G. (2015), Macrophage migration inhibitory factor promotes cyst growth in polycystic kidney disease, Journal of Clinical Investigation 125(6): 2399-2412.
- Spithoven, E.M.; Gastel, M.D.A. van; Messchendorp, A.L.; Casteleijn, N.F.; Drenth, J.P.H.; Gaillard, C.A.; Fijter, J.W. de; Meijer, E.; Peters, D.J.M.; Kappert, P.; Renken, R.J.; Visser, F.W.; Wetzels, J.F.M.; Zietse, R.; Gansevoort, R.T. & DIPAK Consortium (2015), Estimation of Total Kidney Volume in Autosomal Dominant Polycystic Kidney Disease, American Journal of Kidney Diseases 66(5): 792-801.
- Happe, H. & Peters, D.J.M. (2014), Translational research in ADPKD: lessons from animal models, Nature Reviews Nephrology 10(10): 587-601.
- Meijer, E.; Drenth, J.P.H.; d'Agnolo, H.; Casteleijn, N.F.; Fijter, J.W. de; Gevers, T.J.; Kappert, P.; Peters, D.J.M.; Salih, M.; Soonawala, D.; Spithoven, E.M.; Torres, V.E.; Visser, F.W.; Wetzels, J.F.M.; Zietse, R.; Gansevoort, R.T. & DIPAK Consortium (2014), Rationale and Design of the DIPAK 1 Study: A Randomized Controlled Clinical Trial Assessing the Efficacy of Lanreotide to Halt Disease Progression in Autosomal Dominant Polycystic Kidney Disease, American Journal of Kidney Diseases 63(3): 446-455.
- Casteleijn, N.F.; Visser, F.W.; Drenth, J.P.H.; Gevers, T.J.G.; Groen, G.J.; Hogan, M.C.; Gansevoort, R.T. & DIPAK Consortium (2014), A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease, Nephrology Dialysis Transplantation 29: 142-153.
- Kar, A.L. van de; Houge, G.; Shaw, A.C.; Jong, D. de; Belzen, M.J. van; Peters, D.J.M. & Hennekam, R.C.M. (2014), Keloids in Rubinstein-Taybi syndrome: a clinical study, British Journal of Dermatology 171(3): 615-621.
- Hulsteijn, L.T. van; Dulk, A.C. den; Hes, F.J.; Bayley, J.P.; Jansen, J.C. & Corssmit, E.P.M. (2013), No difference in phenotype of the main Dutch SDHD founder mutations, Clinical Endocrinology 79(6): 824-831.
- Rutten, J.W.; Boon, E.M.J.; Liem, M.K.; Dauwerse, J.G.; Pont, M.J.; Vollebregt, E.; Maat-Kievit, A.J.; Ginjaar, H.B.; Lakeman, P.; Duinen, S.G. van; Terwindt, G.M. & Oberstein, S.A.J.L. (2013), Hypomorphic NOTCH3 Alleles Do Not Cause CADASIL in Humans, Human Mutation 34(11): 1486-1489.
- Spithoven, E.M.; Bakker, S.J.L.; Kootstra-Ros, J.E.; Jong, P.E. de; Gansevoort, R.T. & DIPAK Consortium Investigators (2013), Stability of creatinine and cystatin C in whole blood, Clinical Biochemistry 46(15): 1611-1614.
- Streets, A.J.; Wessely, O.; Peters, D.J.M. & Ong, A.C.M. (2013), Hyperphosphorylation of polycystin-2 at a critical residue in disease reveals an essential role for polycystin-1-regulated dephosphorylation, Human Molecular Genetics 22(10): 1924-1939.
- Happe, H.; Wal, A.M. van der; Salvatori, D.C.F.; Leonhard, W.N.; Breuning, M.H.; Heer, E. de & Peters, D.J.M. (2013), Cyst expansion and regression in a mouse model of polycystic kidney disease, Kidney International 83(6): 1099-1108.
- Novalic, Z.; Wal, A.M. van der; Leonhard, W.N.; Koehl, G.; Breuning, M.H.; Geissler, E.K.; Heer, E. de & Peters, D.J.M. (2012), Dose-Dependent Effects of Sirolimus on mTOR Signaling and Polycystic Kidney Disease, Journal of the American Society of Nephrology 23(5): 842-853.
- Peyronnet, R.; Sharif-Naeini, R.; Folgering, J.H.A.; Arhatte, M.; Jodar, M.; Boustany, C. el; Gallian, C.; Tauc, M.; Duranton, C.; Rubera, I.; Lesage, F.; Pei, Y.; Peters, D.J.M.; Somlo, S.; Sachs, F.; Patel, A.; Honore, E. & Duprat, F. (2012), Mechanoprotection by Polycystins against Apoptosis Is Mediated through the Opening of Stretch-Activated K-2P Channels, Cell Reports 1(3): 241-250.
- Losekoot M, Ruivenkamp CA, Tholens AP, Grimbergen JE, Vijfhuizen L, Vermeer S, Dijkman HB, Cornelissen EA, Bongers EM & Peters DJ (2012), Neonatal onset autsomal dominant polycystic kidney disease (ADPKD) in a patient homozygous for a PKD2 missense mutation due to uniparental disomy, Journal of Medical Genetics.
- Ivliev, A.E.; Hoen, P.A.C. 't; Roon-Mom, W.M.C. van; Peters, D.J.M. & Sergeeva, M.G. (2012), Exploring the Transcriptome of Ciliated Cells Using In Silico Dissection of Human Tissues, PLoS ONE 7(4): -.
- Boertien, W.E.; Meijer, E.; Zittema, D.; Dijk, M.A. van; Rabelink, T.J.; Breuning, M.H.; Struck, J.; Bakker, S.J.L.; Peters, D.J.M.; Jong, P.E. de & Gansevoort, R.T. (2012), Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease.
- Happé H, de Heer E & Peters DJ (2012), Morphometric analysis of centrosome position in tissues., Methods in Molecular Biology 839: 249-55.
- Meijer, E.; Gansevoort, R.T.; Jong, P.E. de; Wal, A.M. van der; Leonhard, W.N.; Krey, S.R. de; Born, J. van den; Mulder, G.M.; Goor, H. van; Struck, J.; Heer, E. de & Peters, D.J.M. (2011), Therapeutic potential of vasopressin V2 receptor antagonist in a mouse model for autosomal dominant polycystic kidney disease: optimal timing and dosing of the drug.
- Happe, H.; Heer, E. de & Peters, D.J.M. (2011), Polycystic kidney disease: The complexity of planar cell polarity and signaling during tissue regeneration and cyst formation, BBA - Molecular Basis of Disease 1812(10): 1249-1255.
- Happe, H.; Wal, A.M. van der; Leonhard, W.N.; Kunnen, S.J.; Breuning, M.H.; Heer, E. de & Peters, D.J.M. (2011), Altered Hippo signalling in polycystic kidney disease, Journal of Pathology 224(1): 133-142.
- Dauwerse, J.G.; Dixon, J.; Seland, S.; Ruivenkamp, C.A.L.; Haeringen, A. van; Hoefsloot, L.H.; Peters, D.J.M.; Boers, A.C.D.; Daumer-Haas, C.; Maiwald, R.; Zweier, C.; Kerr, B.; Cobo, A.M.; Toral, J.F.; Hoogeboom, A.J.M.; Lohmann, D.R.; Hehr, U.; Dixon, M.J.; Breuning, M.H. & Wieczorek, D. (2011), Mutations in genes encoding subunits of RNA polymerases I and III cause Treacher Collins syndrome, Nature Genetics 43(1): 20-22.
- Leonhard, W.N.; Wal, A. van der; Novalic, Z.; Kunnen, S.J.; Gansevoort, R.T.; Breuning, M.H.; Heer, E. de & Peters, D.J.M. (2011), Curcumin inhibits cystogenesis by simultaneous interference of multiple signaling pathways: in vivo evidence from a Pkd1-deletion model, AJP - Renal Physiology 300(5): F1193-F1202.
- Haagen, H.H.H.B.M. van; Hoen, P.A.C. 't; Morree, A. de; Roon-Mom, W.M.C. van; Peters, D.J.M.; Roos, M.; Mons, B.; Ommen, G.J. van & Schuemie, M.J. (2011), In silico discovery and experimental validation of new protein-protein interactions., Proteomics 11(5): 843-53.
- Dauwerse, J.G.; Dixon, J.; Seland, S.; Ruivenkamp, C.A.L.; Haeringen, A. van; Hoefsloot, L.H.; Peters, D.J.M.; Boers, A.C.D.; Daumer-Haas, C.; Maiwald, R.; Zweier, C.; Kerr, B.; Cobo, A.M.; Toral, J.F.; Hoogeboom, A.J.M.; Lohmann, D.R.; Hehr, U.; Dixon, M.J.; Breuning, M.H. & Wieczorek, D. (2011), Mutations in genes encoding subunits of RNA polymerases I and III cause Treacher Collins syndrome., Nature Genetics 43(1): 20-2.
- Hassane, S.; Claij, N.; Jodar, M.; Dedman, A.; Lauritzen, I.; Duprat, F.; Koenderman, J.S.; Wal, A. van der; Breuning, M.H.; Heer, E. de; Honore, E.; DeRuiter, M.C. & Peters, D.J.M. (2011), Pkd1-inactivation in vascular smooth muscle cells and adaptation to hypertension, Laboratory Investigation 91(1): 24-32.
- Belzen, M. van; Bartsch, O.; Lacombe, D.; Peters, D.J.M. & Hennekam, R.C.M. (2011), Rubinstein-Taybi syndrome (CREBBP, EP300), European Journal of Human Genetics 19(1): -.
- Liu, M.; Shi, S.; Senthilnathan, S.; Yu, J.; Wu, E.; Bergmann, C.; Zerres, K.; Bogdanova, N.; Coto, E.; Deltas, C.; Pierides, A.; Demetriou, K.; Devuyst, O.; Gitomer, B.; Laakso, M.; Lumiaho, A.; Lamnissou, K.; Magistroni, R.; Parfrey, P.; Breuning, M.; Peters, D.J.M.; Torra, R.; Winearls, C.G.; Torres, V.E.; Harris, P.C.; Paterson, A.D. & Pei, Y. (2010), Genetic variation of DKK3 may modify renal disease severity in ADPKD., Journal of the American Society of Nephrology 21(9): 1510-20.
- Dauwerse, J.G.; Ruivenkamp, C.A.; Hansson, K.; Marijnissen, G.M.; Peters, D.J.M.; Breuning, M.H. & Hilhorst-Hofstee, Y. (2010), A Complex Chromosome 7q Rearrangement Identified in a Patient With Mental Retardation, Anxiety Disorder, and Autistic Features, American Journal of Medical Genetics Part A 152A(2): 427-433.
- Meijer, E.; Boertien, W.E.; Nauta, F.L.; Bakker, S.J.L.; Oeveren, W. van; Rook, M.; Jagt, E.J. van der; Goor, H. van; Peters, D.J.M.; Navis, G.; Jong, P.E. de & Gansevoort, R.T. (2010), Association of Urinary Biomarkers With Disease Severity in Patients With Autosomal Dominant Polycystic Kidney Disease: A Cross-sectional Analysis.
- Hassane, S.; Leonhard, W.N.; Wal, A. van der; Hawinkels, L.J.A.C.; Lantinga-van Leeuwen, I.S.; Dijke, P. ten; Breuning, M.H.; Heer, E. de & Peters, D.J.M. (2010), Elevated TGF beta-Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease, Journal of Pathology 222(1): 21-31.
- Happe H, Leonhard WN, van der Wal A, van de Water B, Lantinga-van Leeuwen IS, Breuning MH, de Heer E & Peters DJM (2009), Toxic tubular injury in kidneys from Pkd1-deletion mice accelerates cystogenesis accompanied by dysregulated planar cell polarity and canonical Wnt signaling pathways, Human Molecular Genetics 18(14): 2532-2542.
- Pei Y, Obaji J, Dupuis A, Paterson AD, Magistroni R, Dicks E, Parfrey P, Cramer B, Coto E & Torra R (2009), Unified Criteria for Ultrasonographic Diagnosis of ADPKD, Journal of the American Society of Nephrology 20(1): 205-212.
- Sharif-Naeini R, Folgering JHA, Bichet D, Duprat F, Lauritzen I, Arhatte M, Jodar M, Dedman A, Chatelain FC & Schulte U (2009), Polycystin-1 and-2 Dosage Regulates Pressure Sensing, Cell 139(3): 587-596.
- Wieczorek D, Bartsch O, Lechno S, Kohlhase J, Peters DJM, Dauwerse H, Gillessen-Kaesbach G, Hennekam RCM & Passarge E (2009), Two Adults With Rubinstein-Taybi Syndrome With Mild Mental Retardation, Glaucoma, Normal Growth and Skull Circumference, and Camptodactyly of Third Fingers, American Journal of Medical Genetics Part A 149A(12): 2849-2854.
- Yu ASL, Kanzawa SA, Usorov A, Leeuwen ISLV & Peters DJM (2008), Tight junction composition is altered in the epithelium of polycystic kidneys, Journal of Pathology 216(1).
- de Heer E & Peters DJM (2008), Innate immunity as a driving force in renal disease, Kidney International 73(1).
- Meijer E, de Jong PE, Peters DJ & Gansevoort RT (2008), Better understanding of ADPKD results in potential new treatment options: ready for the cure?, Journal of Nephrology 21(2).
- Leonhard WN, Roelfsema JH, Leeuwen ISLV, Breuning MH & Peters DJM (2008), Quantification of Cre-mediated recombination by a novel strategy reveals a stable extra-chromosomal deletion-circle in mice, BMC Biotechnology 8.
- de Voer G, Peters D & Taschner PEM (2008), Caenorhabditis elegans as a model for lysosomal storage disorders, BBA - Molecular Basis of Disease 1782(7-8).
- Kaisaki PJ, Bergmann C, Brown JH, Outeda P, Lens XM, Peters DJM, Gretz N, Gauguier D & Bihoreau MT (2008), Genomic organization and mutation screening of the human ortholog of Pkdr1 associated with polycystic kidney disease in the rat, European Journal of Medical Genetics 51(4).
- Bartholdi D, Roelfsema JH, Papadia F, Breuning MH, Niedrist D, Hennekam RC, Schinzel A & Peters DJM (2007), Genetic heterogeneity in Rubinstein-Taybi syndrome: delineation of the phenotype of the first patients carrying mutations in EP300, Journal of Medical Genetics 44(5).
- Hassane S, Claij N, Lantinga-van Leeuwen IS, Van Munsteren JC, Van Lent N, Hanemaaijer R, Breuning MH, Peters DJM & DeRuiter MC (2007), Pathogenic sequence for dissecting aneurysm formation in a hypomorphic polycystic kidney disease 1 mouse modelle, Arteriosclerosis, Thrombosis, and Vascular Biology 27(10).
- Dauwerse JG, de Vries BBA, Wouters CH, Bakker E, Rappold G, Mortier GR, Breuning MH & Peters DJM (2007), A t(4;6)(q12;p23) translocation disrupts a membrane-associated O-acetyl transferase gene (MBOAT1) in a patient with a novel brachydactyly-syndactyly syndrome, European Journal of Human Genetics 15(7).
- Lantinga-van Leeuwen IS, Leonhard WN, van der Wal A, Breuning MH, de Heer E & Peters DJM (2007), Kidney-specific inactivation of the Pkd1 gene induces rapid cyst formation in developing kidneys and a slow onset of disease in adult mice, Human Molecular Genetics 16(24).
- Lantinga-van Leeuwen IS, Leonhard WN, van de Wal A, Breuning MH, Verbeek S, de Heer E & Peters DJM (2006), Transgenic mice expressing tamoxifen-inducible Cre for somatic gene modification in renal epithelial cells, genesis 44(5).
- Claij N & Peters DJM (2006), Teaching molecular genetics: Chapter 2 - Transgenesis and gene targeting: mouse models to study gene function and expression, Pediatric Nephrology 21(3).
- Le NH, van der Wal A, van der Bent P, Lantinga-van Leeuwen IS, Breuning MH, van Dam H, de Heer E & Peters DJM (2005), Increased activity of activator protein-1 transcription factor components ATF2, c-Jun, and c-Fos in human and mouse autosomal dominant polycystic kidney disease, Journal of the American Society of Nephrology 16(9).
- Losekoot M, Haarloo C, Ruivenkamp C, White SJ, Breuning MH & Peters DJM (2005), Analysis of missense variants in the PKHD1-gene in patients with autosomal recessive polycystic kidney disease (ARPKD), Human Genetics 118(2): 185-206.
- Lantinga-van Leeuwen IS, Leonhard WN, Dauwerse H, Baelde HJ, van Oost BA, Breuning MH & Peters DJM (2005), Common regulatory elements in the polycystic kidney disease 1 and 2 promoter regions, European Journal of Human Genetics 13(5).
- Roelfsema JH, White SJ, Ariyurek Y, Bartholdi D, Niedrist D, Papadia F, Bacino CA, den Dunnen JT, van Ommen GJB, Breuning MH, Hennekam RC & Peters DJM (2005), Genetic heterogeneity in Rubinstein-Taybi syndrome: Mutations in both the CBP and EP300 genes cause disease, American Journal of Human Genetics 76(4).
- Lantinga-van Leeuwen IS, Dauwerse JG, Baelde HJ, Leonhard WN, van de Wal A, Ward CJ, Verbeek S, DeRuiter MC, Breuning MH, de Heer E & Peters DJM (2004), Lowering of Pkd1 expression is sufficient to cause polycystic kidney disease, Human Molecular Genetics 13(24).
- Le NH, van der Bent P, Huls G, van de Wetering M, Loghman-Adham M, Ong ACM, Calvet JP, Clevers H, Breuning MH, van Dam H & Peters DJM (2004), Aberrant polycystin-1 expression results in modification of activator protein-1 activity, whereas Wnt signaling remains unaffected, Journal of Biological Chemistry 279(26).
- Scheffers MS, van der Bent P, van de Wal A, van Eendenburg J, Breuning MH, de Heer E & Peters DJM (2004), Altered distribution and co-localization of polycystin-2 with polycystin-1 in MDCK cells after wounding stress, Experimental Cell Research 292(1).
- Jurczyk A, Gromley A, Redick S, Agustin JS, Witman G, Pazour GJ, Peters DJM & Doxsey S (2004), Pericentrin forms a complex with intraflagellar transport proteins and polycystin-2 and is required for primary cilia assembly, Journal of Cell Biology 166(5).
- Aguiari G, Banzi M, Gessi S, Cai YQ, Zeggio E, Manzati E, Piva R, Lambertini E, Ferrari L, Peters DJ, Lanza F, Harris PC, Borea PA, Somlo S & del Senno L (2004), Deficiency of polycystin-2 reduces Ca2+ channel activity and cell proliferation in ADPKD lymphoblastoid cells, FASEB Journal 18(3).
- Kalkhoven E, Roelfsema JH, Teunissen H, den Boer A, Ariyurek Y, Zantema A, Breuning MH, Hennekam RCM & Peters DJM (2003), Loss of CBP acetyltransferase activity by PHD finger mutations in Rubinstein-Taybi syndrome, Human Molecular Genetics 12(4).
- Magistroni R, He N, Wang KR, Andrew R, Johnson A, Gabow P, Dicks E, Parfrey P, Torra R, San-Millan JL, Coto E, Van Dijk M, Breuning M, Peters D, Bogdanova N, Ligabue G, Albertazzi A, Hateboer N, Demetriou K, Pierides A, Deltas C, St George-Hyslop P, Ravine D & Pei Y (2003), Genotype-renal function correlation in type 2 autosomal dominant polycystic kidney disease, Journal of the American Society of Nephrology 14(5).
- Scheffers MS, Le H, van der Bent P, Leonhard W, Prins F, Spruit L, Breuning MH, de Heer E & Peters DJM (2002), Distinct subcellular expression of endogenous polycystin-2 in the plasma membrane and Golgi apparatus of MDCK cells, Human Molecular Genetics 11(1).
- Dauwerse JG, de Die-Smulders CEM, Bakker E, Breuning MH & Peters DJM (2002), Heterozygous truncating mutation in the human homeobox gene GSH2 has no discernable phenotypic effect, Journal of Medical Genetics 39(9).
- Dauwerse JG, Bouman K, van Essen AJ, van der Hout AH, Kolsters G, Breuning MH & Peters DJM (2002), Acrofacial dysostosis in a patient with the TSC2-PKD1 contiguous gene syndrome, Journal of Medical Genetics 39(2).
- Peters DJM & Breuning MH (2001), Autosomal dominant polycystic kidney disease: modification of disease progression, Lancet 358(9291).
- Peters DJM, Ariyurek Y, van Dijk M & Breuning MH (2001), Mutation detection for exons 2 to 10 of the Polycystic Kidney Disease 1 (PKD1)-gene by DGGE, European Journal of Human Genetics 9(12).
- van Dijk MA, Breuning MH, Peters DJM & Chang PC (2000), The ACE insertion/deletion polymorphism has no influence on progression of renal function loss in autosomal dominant polycystic kidney disease.
- Petrij F, Dauwerse HG, Blough RI, Giles RH, van der Smagt JJ, Wallerstein R, Maaswinkel-Mooy PD, van Karnebeek CD, van Ommen GJB, van Haeringen A, Rubinstein JH, Saal HM, Hennekam RCM, Peters DJM & Breuning MH (2000), Diagnostic analysis of the Rubinstein-Taybi syndrome: five cosmids should be used for microdeletion detection and low number of protein truncating mutations.
- Petrij F, Dorsman JC, Dauwerse HG, Giles RH, Peeters T, Hennekam RCM, Breuning MH & Peters DJM (2000), Rubinstein-Taybi syndrome caused by a de novo reciprocal translocation t(2;16)(q38.3;p13.3).
- Hateboer N, Veldhuisen B, Peters D, Breuning MH, San-Millan JL, Bogdanova N, Coto E, von Dijk MA, Afzal AR, Jeffery S, Saggar-Malik AK, Torra R, Dimitrakov D, Martinez I, de Castro SS, Krawczak M & Ravine D (2000), Location of mutations within the PKD2 gene influences clinical outcome.
- Scheffers MS, van der Bent P, Prins F, Spruit L, Breuning MH, Litvinov SV, de Heer E & Peters DJM (2000), Polycystin-1, the product of the polycystic kidney disease 1 gene, co-localizes with desmosomes in MDCK cells, Human Molecular Genetics 9(18).
- Veldhuisen B, Spruit L, Dauwerse HG, Breuning MH & Peters DJM (1999), Genes homologous to the autosomal dominant polycystic kidney disease genes (PKD1 and PKD2).
- Consultant